Pub Date : 2021-01-01DOI: 10.37421/1747-0862.2021.S1.483
Farideh Orooji, S. Naeimi, Mohammad Mehdi Moghani Bashi
Infertility is a growing and effective social disease in family relationships. The importance of controlling and measuring patient risk is determined by the individual's predisposing factors to infertility, genetic and acquired background. Inflammatory disorders are seen in many diseases, and cytokines, including IL22, play a role. IL22 is a precursor cytokine and has a dual role in are associated with increased egg fertility and the expansion of fatal growth. The aim of this study was to investigate the effect of two variants rs86781042 and rs1390124543 in IL22 on female infertility in southern Iran and compare it with healthy individuals. In this case study, evidence was used to study the polymorphism of the IL22 gene in the blood of 200 infertile and healthy patients in Shiraz hospitals, for DNA extraction and purification, using Salting Out and Proteinase K methods, followed by electrophoresis and PCR ARM was used. The results were analysed using SPSS software and Hardy Weinberg equilibrium. According to the results, it seems that the expression of two polymorphisms of IL22 gene is directly related to infertility in women in southern Iran and by using this relationship; it can be used as a biomarker for screening infertile women and diagnosing the disease.
{"title":"Association by Polymorphism of the IL22 Gene in Situations, rs867810424 (A/G) and rs1390124543 (A/G) with a Risk of Infertility in Women","authors":"Farideh Orooji, S. Naeimi, Mohammad Mehdi Moghani Bashi","doi":"10.37421/1747-0862.2021.S1.483","DOIUrl":"https://doi.org/10.37421/1747-0862.2021.S1.483","url":null,"abstract":"Infertility is a growing and effective social disease in family relationships. The importance of controlling and measuring patient risk is determined by the individual's predisposing factors to infertility, genetic and acquired background. Inflammatory disorders are seen in many diseases, and cytokines, including IL22, play a role. IL22 is a precursor cytokine and has a dual role in are associated with increased egg fertility and the expansion of fatal growth. The aim of this study was to investigate the effect of two variants rs86781042 and rs1390124543 in IL22 on female infertility in southern Iran and compare it with healthy individuals. In this case study, evidence was used to study the polymorphism of the IL22 gene in the blood of 200 infertile and healthy patients in Shiraz hospitals, for DNA extraction and purification, using Salting Out and Proteinase K methods, followed by electrophoresis and PCR ARM was used. The results were analysed using SPSS software and Hardy Weinberg equilibrium. According to the results, it seems that the expression of two polymorphisms of IL22 gene is directly related to infertility in women in southern Iran and by using this relationship; it can be used as a biomarker for screening infertile women and diagnosing the disease.","PeriodicalId":88269,"journal":{"name":"Journal of molecular and genetic medicine : an international journal of biomedical research","volume":"1 1","pages":"1-4"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70041544","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-01-01DOI: 10.37421/1747-0862.2021.15.491
Pour Pm
Introduction: Breast cancer is one of the most common types of cancer among women and is the first cause of cancer deaths in women. According to world health statistics, one out of every 8 to 10 women develops breast cancer. According to Iran statistics, out of every 10 to 15 women in our country, one woman has probably breast cancer, so the aim of this study was to investigate the relation between ADSL gene rs3788577 polymorphism, rs7816345 polymorphism (near znf703 gene) and rs17001868 polymorphism associated with SGSM3 gene with breast cancer in the population of East Azerbaijan. Methods: In this study, 100 samples from patients with breast cancer and 100 blood samples from healthy individuals were selected as control group. Then, according to the protocol, DNA was extracted from all samples with the DNA extraction kit. Electrophoresis was then carried out to assure the quality of the extracted DNA, and quantified by spectrophotometer. The samples were then PCR-amplified with specific primers and finally "PCR products were treated with the restriction enzyme and electrophoresed on agarose gel". Data were analyzed by SPSS software version 10 using descriptive and chi-square tests and significance level less than 0.05 was considered. Results: The results of ADSL gene rs3788577 polymorphism analysis showed that the percentage of G allele was 14.5% and 18.1% in healthy and diseased individuals, respectively. Examination of these data shows that the G-allele has a 44% increase in diseased people compared to healthy people. The results of SGSM3 gene polymorphism 17001868 showed that the percentage of T-allele was 15% and 21.5%, respectively. The examination of these results showed that T-allele increased 6.5% in healthy individuals and also rs7816345 polymorphism results showed that the percentage of T-allele in healthy subjects was reported to be 44.5% and 69.5%. Examination of these data shows that the T-allele has an 11% increase in diseased people compared to healthy people. Discussion: Polymorphism analysis of rs378857 rs7816345 showed that there is probably a relationship between increased G allele (44%) and increased T allele (25%) respectively and the incidence of breast cancer and its prevalence in Azerbaijan population. On the other hand, rs 17001868 polymorphism analysis showed that there is "probably no relation between the T allele increase (by 6.5%) and the incidence of breast cancer. Conclusion: Given that current methods of treatment for all types of cancers have serious consequences, discovering new ways to diagnose the disease early by identifying specific biomarkers for that type of cancer is essential and can open new therapeutic horizons.
{"title":"The Investigation of the Relation of rs7816345, rs17001868 and rs3788577 Polymorphisms with Breast Cancer in the Population of East Azerbaijan","authors":"Pour Pm","doi":"10.37421/1747-0862.2021.15.491","DOIUrl":"https://doi.org/10.37421/1747-0862.2021.15.491","url":null,"abstract":"Introduction: Breast cancer is one of the most common types of cancer among women and is the first cause of cancer deaths in women. According to world health statistics, one out of every 8 to 10 women develops breast cancer. According to Iran statistics, out of every 10 to 15 women in our country, one woman has probably breast cancer, so the aim of this study was to investigate the relation between ADSL gene rs3788577 polymorphism, rs7816345 polymorphism (near znf703 gene) and rs17001868 polymorphism associated with SGSM3 gene with breast cancer in the population of East Azerbaijan. Methods: In this study, 100 samples from patients with breast cancer and 100 blood samples from healthy individuals were selected as control group. Then, according to the protocol, DNA was extracted from all samples with the DNA extraction kit. Electrophoresis was then carried out to assure the quality of the extracted DNA, and quantified by spectrophotometer. The samples were then PCR-amplified with specific primers and finally \"PCR products were treated with the restriction enzyme and electrophoresed on agarose gel\". Data were analyzed by SPSS software version 10 using descriptive and chi-square tests and significance level less than 0.05 was considered. Results: The results of ADSL gene rs3788577 polymorphism analysis showed that the percentage of G allele was 14.5% and 18.1% in healthy and diseased individuals, respectively. Examination of these data shows that the G-allele has a 44% increase in diseased people compared to healthy people. The results of SGSM3 gene polymorphism 17001868 showed that the percentage of T-allele was 15% and 21.5%, respectively. The examination of these results showed that T-allele increased 6.5% in healthy individuals and also rs7816345 polymorphism results showed that the percentage of T-allele in healthy subjects was reported to be 44.5% and 69.5%. Examination of these data shows that the T-allele has an 11% increase in diseased people compared to healthy people. Discussion: Polymorphism analysis of rs378857 rs7816345 showed that there is probably a relationship between increased G allele (44%) and increased T allele (25%) respectively and the incidence of breast cancer and its prevalence in Azerbaijan population. On the other hand, rs 17001868 polymorphism analysis showed that there is \"probably no relation between the T allele increase (by 6.5%) and the incidence of breast cancer. Conclusion: Given that current methods of treatment for all types of cancers have serious consequences, discovering new ways to diagnose the disease early by identifying specific biomarkers for that type of cancer is essential and can open new therapeutic horizons.","PeriodicalId":88269,"journal":{"name":"Journal of molecular and genetic medicine : an international journal of biomedical research","volume":"15 1","pages":"1-6"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70061792","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-01-01DOI: 10.37421/1747-0862.2021.15.486
Jiang Sw
{"title":"Editorial Note for Covid-19 Symptoms","authors":"Jiang Sw","doi":"10.37421/1747-0862.2021.15.486","DOIUrl":"https://doi.org/10.37421/1747-0862.2021.15.486","url":null,"abstract":"","PeriodicalId":88269,"journal":{"name":"Journal of molecular and genetic medicine : an international journal of biomedical research","volume":"15 1","pages":"1-1"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70061849","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-01-01DOI: 10.37421/1747-0862.2021.15.497
Jiang Sw
{"title":"Editorial Note on Genetic Diseases","authors":"Jiang Sw","doi":"10.37421/1747-0862.2021.15.497","DOIUrl":"https://doi.org/10.37421/1747-0862.2021.15.497","url":null,"abstract":"","PeriodicalId":88269,"journal":{"name":"Journal of molecular and genetic medicine : an international journal of biomedical research","volume":"15 1","pages":"1-1"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70061543","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-01-01DOI: 10.37421/1747-0862.2021.15.498
W. Wang
{"title":"Editorial Note on Genetic Screening","authors":"W. Wang","doi":"10.37421/1747-0862.2021.15.498","DOIUrl":"https://doi.org/10.37421/1747-0862.2021.15.498","url":null,"abstract":"","PeriodicalId":88269,"journal":{"name":"Journal of molecular and genetic medicine : an international journal of biomedical research","volume":"15 1","pages":"1-1"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70061559","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-01-01DOI: 10.37421/1747-0862.2021.15.503
R. Thakur, N. Kohn, Brown Mh
Carfilzomib is an irreversible proteasome inhibitor (PI), first approved in 2012 for treatment of relapsed refractory multiple myeloma (RRMM). The real-world use of carfilzomib in treatment of RRMM is important to assess. The objectives of this study are to evaluate the real-world outcome in overall response rates (ORR), progression-free survival (PFS), and adverse drug events (ADEs), including cardiotoxicity and nephrotoxicity for RRMM patients treated with carfilzomib. We retrospectively analyzed the charts of patients with a diagnosis of MM treated with carfilzomib between January 2013 and December 2018. Demographics, cytogenetics, fluorescence in situ hybridization (FISH), and treatment history were collected. Sixty-six patients fit the study criteria, with median age of 65 years (range 48 - 84). Using the Revised International Staging System (R-ISS), 7 (10.6%) patients were stage I, 28 (42.4%) stage II, and 31 (47.0%) stage III. Cytogenetics showed 33 (48.5%) were high risk. Eight (12.12%) patients were pretreated with more than 4 treatment lines and 27 (40.95) had an autologous stem cell transplant (ASCT) prior to carfilzomib. Prior treatments included lenalidomide, bortezomib, and cyclophosphamide-based regimens. The ORR was 77.2%, with 4 (6.2%) complete responses (CR). Ten patients (15%) received ASCT after carfilzomib for progression of disease (POD). The majority with POD received daratumumab (40%) or pomalidomide (46%). Grade 2 hypertension was noted in 9 (13.6%) patients, acute renal failure (ARF) in 11 (16.7%) and heart failure (HF) in 12 (18.2%). The median PFS on Carfilzomib was 6.96 months. This study showed carfilzomib improved PFS in patients with RRMM; however, there is increased risk for cardiac and renal toxicity, greater than previously reported in the literature. This study reinforces the importance for oncologists to be aware of these toxicities. Astute awareness, early monitoring, and prevention may favorably impact outcomes with use of carfilzomib.
{"title":"Treatment Outcomes and Toxicity Profile of Carfilzomib in Multiple Myeloma: A Single Institution Experience","authors":"R. Thakur, N. Kohn, Brown Mh","doi":"10.37421/1747-0862.2021.15.503","DOIUrl":"https://doi.org/10.37421/1747-0862.2021.15.503","url":null,"abstract":"Carfilzomib is an irreversible proteasome inhibitor (PI), first approved in 2012 for treatment of relapsed refractory multiple myeloma (RRMM). The real-world use of carfilzomib in treatment of RRMM is important to assess. The objectives of this study are to evaluate the real-world outcome in overall response rates (ORR), progression-free survival (PFS), and adverse drug events (ADEs), including cardiotoxicity and nephrotoxicity for RRMM patients treated with carfilzomib. We retrospectively analyzed the charts of patients with a diagnosis of MM treated with carfilzomib between January 2013 and December 2018. Demographics, cytogenetics, fluorescence in situ hybridization (FISH), and treatment history were collected. Sixty-six patients fit the study criteria, with median age of 65 years (range 48 - 84). Using the Revised International Staging System (R-ISS), 7 (10.6%) patients were stage I, 28 (42.4%) stage II, and 31 (47.0%) stage III. Cytogenetics showed 33 (48.5%) were high risk. Eight (12.12%) patients were pretreated with more than 4 treatment lines and 27 (40.95) had an autologous stem cell transplant (ASCT) prior to carfilzomib. Prior treatments included lenalidomide, bortezomib, and cyclophosphamide-based regimens. The ORR was 77.2%, with 4 (6.2%) complete responses (CR). Ten patients (15%) received ASCT after carfilzomib for progression of disease (POD). The majority with POD received daratumumab (40%) or pomalidomide (46%). Grade 2 hypertension was noted in 9 (13.6%) patients, acute renal failure (ARF) in 11 (16.7%) and heart failure (HF) in 12 (18.2%). The median PFS on Carfilzomib was 6.96 months. This study showed carfilzomib improved PFS in patients with RRMM; however, there is increased risk for cardiac and renal toxicity, greater than previously reported in the literature. This study reinforces the importance for oncologists to be aware of these toxicities. Astute awareness, early monitoring, and prevention may favorably impact outcomes with use of carfilzomib.","PeriodicalId":88269,"journal":{"name":"Journal of molecular and genetic medicine : an international journal of biomedical research","volume":"15 1","pages":"1-5"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70061664","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-01-01DOI: 10.37421/1747-0862.2021.15.504
Diaga Sp, D. Djp, D. Yacouba, Abdoul Bas, Mawulolo Gf, T. Silly, M. Babacar, Maguette Sn, F. Oumar, D. Alioune, Rokhaya Nd
Oral cancers are heterogeneous group of tumors in topography (they can be localized at on the lips, tongue, upper and lower gums, hard and soft palates, floor of mouth, retromolar region, or inside of cheek), histologic forms (that can be carcinoma, sarcoma, lymphoma, melanoma or cylindroma) and clinical outcomes (good or poor prognosis). However, more than 50% of these cancer phenotypes express a mutation at TP53 gene while in the other 50% of cases; the TP53 protein pathway is often partially inactivated. In cancerous tissues, particularly in oral squamous cells, the loss of function at TP53 gene is associated with three molecular causes: (1) The genotoxic effect of risk factors such as alcohol abuse, tobacco smoking or betel nut chewing, (2) The inhibitory effect of the TP53 antagonist genes such as MDM2, or (3) The action of oncoproteins of high-risk human papillomavirus (HPV). This paper attempts firstly to make an exhaustive review of TP53 gene signalling pathways in normal and stressed cells, and secondly to describe in oral cancers the genetic events that occur at different steps of carcinogenesis after a loss of function in TP53 encoded protein.
{"title":"TP53 Gene Signaling Pathways and Protein Interactions with MDM2 and HPV in Oral Cancers andndash; A Review","authors":"Diaga Sp, D. Djp, D. Yacouba, Abdoul Bas, Mawulolo Gf, T. Silly, M. Babacar, Maguette Sn, F. Oumar, D. Alioune, Rokhaya Nd","doi":"10.37421/1747-0862.2021.15.504","DOIUrl":"https://doi.org/10.37421/1747-0862.2021.15.504","url":null,"abstract":"Oral cancers are heterogeneous group of tumors in topography (they can be localized at on the lips, tongue, upper and lower gums, hard and soft palates, floor of mouth, retromolar region, or inside of cheek), histologic forms (that can be carcinoma, sarcoma, lymphoma, melanoma or cylindroma) and clinical outcomes (good or poor prognosis). However, more than 50% of these cancer phenotypes express a mutation at TP53 gene while in the other 50% of cases; the TP53 protein pathway is often partially inactivated. In cancerous tissues, particularly in oral squamous cells, the loss of function at TP53 gene is associated with three molecular causes: (1) The genotoxic effect of risk factors such as alcohol abuse, tobacco smoking or betel nut chewing, (2) The inhibitory effect of the TP53 antagonist genes such as MDM2, or (3) The action of oncoproteins of high-risk human papillomavirus (HPV). This paper attempts firstly to make an exhaustive review of TP53 gene signalling pathways in normal and stressed cells, and secondly to describe in oral cancers the genetic events that occur at different steps of carcinogenesis after a loss of function in TP53 encoded protein.","PeriodicalId":88269,"journal":{"name":"Journal of molecular and genetic medicine : an international journal of biomedical research","volume":"15 1","pages":"1-11"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70061710","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-01-01DOI: 10.37421/1747-0862.2021.15.493
Funjan Aia
A neurosurgery is made by Helicase 4 to 6 genes of Epstein Barr Virus (4 to 6 Helicase gene of EBV); for this was it is made to surge tumor cells in patients of Medulloblastoma and Glioma in both animals and human clinical trial phase-III. In this case it will act by surgical procedure himself (surgical Neurooncology procedure) by acting as neurosurgeon inside tumor cells in both patients of Medulloblastoma and Glioma of human and mice phase –III; in this case the well doing is seizure of gene 5 of EBV and the other is scalpel. Of these tumors (Medulloblastoma and Glioma) of animal cells and human 10% were fully treated by removing NOTCHES of c-AMP of Medulloblastoma (neuroprimitive ectodermal tumors of cerebellum in embryo and children) and primitive neuroectodermal sheath of skull (Glioma in young and adults) by Helicase gene 4 and 6 (scalpel process). Other issue is to find a medium inside cerebrospinal fluid (CSF) of both tumors by Helicase gene itself in destroying plasmodesmata between cells of tumor by artificial plasmosomes (synthesized in self-funded laboratories). The EBV is fully power in its enzyme (Helicase gene from 4 to 6 with fully length density 2000 of plasmosomes due to it will act as a neurosurgeon in its needed. Other thing it will act as scalpel in its issue without any toxic side effects.
{"title":"A Study on Advanced Surgical Neurooncology","authors":"Funjan Aia","doi":"10.37421/1747-0862.2021.15.493","DOIUrl":"https://doi.org/10.37421/1747-0862.2021.15.493","url":null,"abstract":"A neurosurgery is made by Helicase 4 to 6 genes of Epstein Barr Virus (4 to 6 Helicase gene of EBV); for this was it is made to surge tumor cells in patients of Medulloblastoma and Glioma in both animals and human clinical trial phase-III. In this case it will act by surgical procedure himself (surgical Neurooncology procedure) by acting as neurosurgeon inside tumor cells in both patients of Medulloblastoma and Glioma of human and mice phase –III; in this case the well doing is seizure of gene 5 of EBV and the other is scalpel. Of these tumors (Medulloblastoma and Glioma) of animal cells and human 10% were fully treated by removing NOTCHES of c-AMP of Medulloblastoma (neuroprimitive ectodermal tumors of cerebellum in embryo and children) and primitive neuroectodermal sheath of skull (Glioma in young and adults) by Helicase gene 4 and 6 (scalpel process). Other issue is to find a medium inside cerebrospinal fluid (CSF) of both tumors by Helicase gene itself in destroying plasmodesmata between cells of tumor by artificial plasmosomes (synthesized in self-funded laboratories). The EBV is fully power in its enzyme (Helicase gene from 4 to 6 with fully length density 2000 of plasmosomes due to it will act as a neurosurgeon in its needed. Other thing it will act as scalpel in its issue without any toxic side effects.","PeriodicalId":88269,"journal":{"name":"Journal of molecular and genetic medicine : an international journal of biomedical research","volume":"15 1","pages":"1-3"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70061864","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-01-01DOI: 10.37421/1747-0862.2021.15.488
Jiang Sw
{"title":"Editorial Note for How to Treat Coronavirus at Home","authors":"Jiang Sw","doi":"10.37421/1747-0862.2021.15.488","DOIUrl":"https://doi.org/10.37421/1747-0862.2021.15.488","url":null,"abstract":"","PeriodicalId":88269,"journal":{"name":"Journal of molecular and genetic medicine : an international journal of biomedical research","volume":"15 1","pages":"1-1"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70061966","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-01-01DOI: 10.37421/1747-0862.2021.15.489
B. Rita
{"title":"Editorial Note for Cell Systems Biology","authors":"B. Rita","doi":"10.37421/1747-0862.2021.15.489","DOIUrl":"https://doi.org/10.37421/1747-0862.2021.15.489","url":null,"abstract":"","PeriodicalId":88269,"journal":{"name":"Journal of molecular and genetic medicine : an international journal of biomedical research","volume":"15 1","pages":"1-1"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70061975","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：